What is First-Line Treatment for Follicular Lymphoma?

When your doctor determines it is time to move from “watch and wait” to active treatment for follicular lymphoma, your first treatment (called first-line therapy) is typically a combination of two drugs given over about 4 to 6 months. For the vast majority of patients, this involves an immunotherapy drug paired with either chemotherapy or a targeted oral medication ^[1].

Because follicular lymphoma grows slowly, the goal of first-line treatment is to put the disease into a long-term remission, alleviate any symptoms, and maintain your quality of life ^[2][3].

The Foundation: Monoclonal Antibodies

Almost all first-line regimens for follicular lymphoma are built around a monoclonal antibody—a type of immunotherapy that flags and destroys B-cells (the white blood cells where follicular lymphoma starts). You will often see these called anti-CD20 drugs because they target a specific protein called CD20 on the surface of the lymphoma cells. The two standard options are:

• Rituximab: The most commonly used antibody, which has been a standard treatment for decades.
• Obinutuzumab: A newer, highly engineered antibody designed to trigger a stronger immune response ^[4].

Research shows that obinutuzumab keeps the disease away longer than rituximab ^[5][4]. However, obinutuzumab also carries a slightly higher risk of side effects, such as low white blood cell counts and infusion reactions (fever, chills, or blood pressure drops during the IV drip) ^[6][7]. Overall survival rates are similar with either drug ^[5]. To help prevent infusion reactions, nurses will give you pre-medications like Tylenol and Benadryl before your treatment begins.

Option 1: Chemoimmunotherapy (Antibody + Chemotherapy)

The most common approach is pairing your antibody with chemotherapy, often referred to as chemoimmunotherapy. The treatment is usually given as an IV infusion at a clinic once every few weeks. Your doctor may recommend one of the following chemotherapy “backbones”:

• Bendamustine (BR or G-B): The most frequently used chemotherapy for follicular lymphoma. Studies show it is highly effective at keeping the disease in remission and generally causes fewer severe side effects (like hair loss or nerve damage) than stronger chemotherapies ^[8][9].
• CHOP (R-CHOP or G-CHOP): A combination of three IV chemotherapy drugs plus a steroid pill. This is often reserved for patients who have more aggressive disease features or tumors that are growing rapidly ^[10].
• CVP (R-CVP or G-CVP): A milder chemotherapy combination that might be used for patients who cannot tolerate stronger drugs, though it is used less often today.

(Note: The “R” stands for rituximab and “G” stands for obinutuzumab, which is sold under the brand name Gazyva).

Option 2: The “Chemo-Free” Route (The R2 Regimen)

If you prefer to avoid traditional chemotherapy, your doctor may suggest the R2 regimen. This combines rituximab IV infusions with lenalidomide, a daily pill you take at home that alters the immune system to help it fight cancer cells ^[11][12].

Clinical trials have shown that the R2 regimen is just as effective at putting follicular lymphoma into remission as traditional chemoimmunotherapy ^[13][13]. While it avoids chemotherapy side effects like hair loss and severe immune suppression, it has its own unique side effects, such as a higher rate of skin rashes ^[13]. Because lenalidomide carries a risk of blood clots, patients on this regimen typically need to take a daily aspirin or blood thinner ^[11].

The Next Steps: Scans and Maintenance

After you complete your 4 to 6 months of first-line therapy, your doctor will likely order a PET or CT scan to confirm that the treatment worked and the lymphoma has shrunk.

Depending on your results and the treatments you received, your doctor may discuss the option of maintenance therapy. This involves getting a single infusion of your monoclonal antibody (rituximab or obinutuzumab) once every two months for about two years. Research shows that maintenance therapy significantly delays the return of the disease ^[14][15]. However, it does not necessarily improve overall survival and carries an increased risk of long-term infections ^[6]. Together with your doctor, you can weigh the benefit of delaying a relapse against the risk of ongoing side effects to decide if maintenance therapy is right for you.